Sanofi (NASDAQ:SNY) Upgraded to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Sanofi (NASDAQ:SNY) from a hold rating to a buy rating in a research report report published on Saturday morning.

Several other equities analysts have also commented on the company. Morgan Stanley set a $49.00 price objective on Sanofi in a research report on Wednesday, July 8th. Weiss Ratings raised shares of Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, May 13th. Argus upgraded shares of Sanofi to a “strong-buy” rating in a research note on Monday, April 27th. Citigroup reissued a “neutral” rating on shares of Sanofi in a research report on Monday, April 13th. Finally, BNP Paribas Exane lowered shares of Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price objective on the stock. in a research note on Monday, April 20th. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and ten have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Sanofi currently has a consensus rating of “Hold” and a consensus price target of $49.50.

Sanofi Trading Up 0.4%

SNY opened at $43.08 on Friday. The company has a quick ratio of 0.22, a current ratio of 1.01 and a debt-to-equity ratio of 0.17. Sanofi has a 52 week low of $40.89 and a 52 week high of $52.68. The stock has a market cap of $104.44 billion, a PE ratio of 22.55, a PEG ratio of 1.09 and a beta of 0.34. The business has a 50 day moving average of $43.43 and a 200-day moving average of $45.21.

Hedge Funds Weigh In On Sanofi

Large investors have recently modified their holdings of the stock. Flagship Harbor Advisors LLC purchased a new stake in Sanofi during the 4th quarter valued at about $25,000. Physician Wealth Advisors Inc. increased its stake in Sanofi by 180.5% during the 1st quarter. Physician Wealth Advisors Inc. now owns 589 shares of the company’s stock valued at $28,000 after purchasing an additional 379 shares in the last quarter. Leonteq Securities AG raised its holdings in Sanofi by 95.8% in the first quarter. Leonteq Securities AG now owns 607 shares of the company’s stock worth $29,000 after buying an additional 297 shares during the last quarter. Western Wealth Management LLC purchased a new position in Sanofi in the first quarter worth about $29,000. Finally, Measured Wealth Private Client Group LLC bought a new position in shares of Sanofi in the third quarter worth approximately $29,000. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Trending Headlines about Sanofi

Here are the key news stories impacting Sanofi this week:

• Positive Sentiment: Sanofi reported second-quarter earnings of $1.19 per share, exceeding the $1.10 analyst consensus, while revenue rose 16% year over year to $14.04 billion, above expectations of $13.02 billion. Sanofi quarterly earnings report
• Positive Sentiment: Strong demand for blockbuster immunology drug Dupixent drove the results, with quarterly sales surpassing €5 billion for the first time. The performance led Sanofi to raise its 2026 outlook, targeting roughly 10% sales growth excluding currency effects and slightly faster growth in business earnings per share. Sanofi raises sales outlook on Dupixent strength
• Neutral Sentiment: Unusually high options activity showed traders purchased 4,046 call options, 74% above average daily volume. This may indicate increased bullish speculation, but it does not necessarily signal a change in the company’s fundamentals.
• Negative Sentiment: Management acknowledged that weak decision-making and execution hurt the pipeline. The new CEO plans to overhaul and prioritize R&D, raising concerns about the timing and strength of future product launches. Sanofi discusses pipeline and R&D discipline
• Negative Sentiment: The positive earnings and guidance news was overshadowed by pipeline setbacks, leaving investors focused on whether Dupixent’s momentum can offset longer-term portfolio risks. Sanofi beats earnings but faces pipeline setbacks

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.